Table 1.
Baseline demographics and clinical characteristics
| All patients (N = 138) | |
|---|---|
| Male/female, n (%) | 84/54 (61/39) |
| Age years) | |
| Median (range) | 61 (25, 90) |
| ≥65 years, n (%) | 54 (39) |
| Karnofsky performance status, n (%) | |
| 100 | 33 (24) |
| 90 | 63 (46) |
| 80 | 22 (16) |
| 70 | 14 (10) |
| 60 | 6 (4) |
| Number of sites of disease, n (%) | |
| 1 | 51 (37) |
| 2 | 55 (40) |
| 3 | 27 (20) |
| ≥4 | 5 (4) |
| Imatinib resistance, n (%)a | |
| Primary | 47 (34) |
| Secondary | 91 (66) |
| Prior chemotherapy, n (%) | |
| None | 117 (85) |
| 1 Regimen | 11 (8) |
| ≥2 Regimens | 10 (7) |
| Duration of first imatinib therapy, n (%) | |
| ≤6 months | 34 (25) |
| >6 months | 104 (75) |
| Total duration of imatinib therapy (months) | |
| Median (range) | 33 (4, 57) |
| Best response to initial imatinib, n (%) | |
| Complete response | 4 (3) |
| Partial response | 48 (35) |
| Stable disease | 39 (28) |
| Progressive disease | 47 (34) |
| Highest imatinib dose administered (mg), n (%) | |
| 600 | 21 (15) |
| 700 | 1 (1) |
| 800 | 108 (78) |
| 1,000 | 4 (3) |
| 1,100 | 1 (1) |
| 1,200 | 3 (2) |
aPrimary resistance: failure to achieve stable disease in response to imatinib or development of disease progression within 6 months of an initial clinical response to imatinib. Secondary resistance: development of one or more sites of disease progression after more than 6 months of clinical response to imatinib